Vanda Pharmaceuticals | VNDA - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 8.56M 7.13M 2026-06
AstraZeneca USD 18.86B 972M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Halozyme Therapeutics USD 453.33M 4.66M 2026-06
Heron Therapeutics USD 89.59M 8.54M 2025-12
Insmed USD 215.32M 36.77M 2026-06
J&J USD 22.54B 1.21B 2026-03
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
Ligand Pharmaceuticals USD 54.8M 6.25M 2026-03
Merck USD 12.21B 435M 2026-03
Moderna USD 17M 54M 2026-06
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 16.19B 19M 2026-06
PTC Therapeutics USD 219.92M 38.3M 2026-03
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 492M 10M 2026-06
Takeda JPY 956.14B 79.79B 2026-06
Teva Pharmaceutical Industries USD 3.49B 100M 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Veracyte USD 54.18M 4.06M 2026-06